



## Clinical trial results:

**A randomised controlled feasibility trial comparing clinical and cost effectiveness of cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) and their combination in the management of obsessive compulsive disorder.**

### Summary

EudraCT number	2013-003219-22
Trial protocol	GB
Global end of trial date	17 July 2017

### Results information

Result version number	v1 (current)
This version publication date	05 July 2019
First version publication date	05 July 2019
Summary attachment (see zip file)	Letter to MHRA re Final Report (letter to MHRA re Final Report signed.pdf) Final Report Summary (Optimal Treatment for OCD Final Report Summary 1.1 (2).docx) Final Data Report (OTO Final Data Report v1.0 29Jun2018.docx) Knowledge Exchange Meeting (OTO Knowledge Exchange Meeting Summary v1.0.docx) OTO Final Report (OTO-finalreport-12th nov 2017 finalrev.doc)

### Trial information

#### Trial identification

Sponsor protocol code	LMS/SF/UH/0018
-----------------------	----------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	University of Hertfordshire
Sponsor organisation address	College lane, Hatfield, Hertfordshire, United Kingdom, AL10 9AB
Public contact	Solange Wyatt, University of Hertfordshire, +44 1707284642, s.wyatt5@herts.ac.uk
Scientific contact	Solange Wyatt, University of Hertfordshire, +44 1707284642, s.wyatt5@herts.ac.uk

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No	No

1901/2006 apply to this trial?	
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 July 2017
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	17 July 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main research question is to find out whether it is possible to carry out a randomised study looking at whether sertraline alone or cognitive behavioural therapy alone or a combination of both sertraline and cognitive behavioural therapy is better in treating obsessive compulsive disorder (OCD). The study will look at what obstacles there are in recruiting into a large trial, the practicality of delivering treatment and the acceptability to patients. Symptom changes, quality of life changes and resource use will also be assessed.

Protection of trial subjects:

Patients given a 24hr contact number of Clinical staff if experiencing distress

Background therapy: -

Evidence for comparator:

All treatments are standard of care

Actual start date of recruitment	05 February 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 49
Worldwide total number of subjects	49
EEA total number of subjects	49

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	49
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study recruited across 3 sites. 258 potential participants, 66 were screened and 49 entered the study. 15 randomised to Sertraline Monotherapy (Arm A), 18 randomised to the combination arm (Arm B) and 16 participants allocated Cognitive Behavioural Therapy (CBT) with Exposure and Response Prevention (ERP) Monotherapy (Arm C).

### Pre-assignment

Screening details:

1. Community-based service-users, aged 18-65 years 2. DSM-IV OCD, determined by a research psychiatrist using the Mini International Neuropsychiatric Inventory (MINI) for DSM-IV (version 6.0) 3. Duration of symptoms >1 year (from medical history) 4. Baseline score >16 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

### Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind <sup>[1]</sup>
Roles blinded	Data analyst, Assessor <sup>[2]</sup>

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Sertraline hydrochloride (Arm A)

Arm description:

Sertraline hydrochloride Monotherapy

Arm type	Experimental
Investigational medicinal product name	Sertraline Hydrochloride
Investigational medicinal product code	MIA (IMP)11149
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

The treatment for patients randomised to Arm A will be Sertraline hydrochloride (50-200mg) monotherapy once a day for 52 weeks.

Sertraline will be flexibly up-titrated from 50-200mg in accordance with the licence and guided by tolerability and clinician-based judgement. Doses may be adjusted upwards or downwards for the first 8 weeks, aiming for the 200mg dose if tolerated

<b>Arm title</b>	Arm B
------------------	-------

Arm description:

Cognitive Behavioural Therapy (CBT) with Exposure Response Prevention monotherapy for a total of 16 hours over 8 weeks

Arm type	Behavioural Treatment
No investigational medicinal product assigned in this arm	
<b>Arm title</b>	Combination (Arm C)

Arm description:

A combination of Sertraline hydrochloride and Cognitive Behavioural Therapy (CBT) with Exposure Response Prevention (ERP)

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Sertraline Hydrochloride
Investigational medicinal product code	MIA (IMP)11149
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

The treatment for patients randomised to Arm C will include Sertraline hydrochloride (50-200mg) monotherapy once a day for 52 weeks.

Sertraline will be flexibly up-titrated from 50-200mg in accordance with the licence and guided by tolerability and clinician-based judgement. Doses may be adjusted upwards or downwards for the first 8 weeks, aiming for the 200mg dose if tolerated

Additionally subjects receive CBT and ERP

Notes:

[1] - The number of roles blinded appears inconsistent with a single blinded trial. It is expected that there will be one role blinded in a single blind trial.

Justification: This was a partially blinded study as one treatment was obvious to patients, statistician and assessor were the only blinded parties

[2] - The roles blinded appear inconsistent with a simple blinded trial.

Justification: This was a partially blinded study as one treatment was obvious to patients, statistician and assessor were the only blinded parties

<b>Number of subjects in period 1</b>	Sertraline hydrochloride (Arm A)	Arm B	Combination (Arm C)
Started	15	16	18
8 week Follow UP	9	12	14
52 week Follow up	6	8	9
Completed	6	8	9
Not completed	9	8	9
Consent withdrawn by subject	6	4	9
Lost to follow-up	3	4	-

## Baseline characteristics

### Reporting groups

Reporting group title	Overall Trial
Reporting group description:	
-	

Reporting group values	Overall Trial	Total	
Number of subjects	49	49	
Age categorical			
Treatment-seeking adult OCD patients (aged 18-65yrs) with DSM-IV OCD52 using the MINI for DSM-IV, with a duration of symptoms >1 year and a baseline score >16 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	49	49	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	28	28	
Male	21	21	

### Subject analysis sets

Subject analysis set title	Full Analysis
Subject analysis set type	Full analysis
Subject analysis set description:	
randomised patients	

Reporting group values	Full Analysis		
Number of subjects	49		
Age categorical			
Treatment-seeking adult OCD patients (aged 18-65yrs) with DSM-IV OCD52 using the MINI for DSM-IV, with a duration of symptoms >1 year and a baseline score >16 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		

Adolescents (12-17 years)	0		
Adults (18-64 years)	49		
From 65-84 years	0		
85 years and over	0		
Gender categorical			
Units: Subjects			
Female	28		
Male	21		

---

## End points

### End points reporting groups

Reporting group title	Sertraline hydrochloride (Arm A)
Reporting group description:	
Sertraline hydrochloride Monotherapy	
Reporting group title	Arm B
Reporting group description:	
Cognitive Behavioural Therapy (CBT) with Exposure Response Prevention monotherapy for a total of 16 hours over 8 weeks	
Reporting group title	Combination (Arm C)
Reporting group description:	
A combination of Sertraline hydrochloride and Cognitive Behavioural Therapy (CBT) with Exposure Response Prevention (ERP)	
Subject analysis set title	Full Analysis
Subject analysis set type	Full analysis
Subject analysis set description:	
randomised patients	

### Primary: Variation of the primary outcome

End point title	Variation of the primary outcome <sup>[1]</sup>
End point description:	
To estimate the variation of the primary outcome measure, the Y-BOCS, both within and between the three treatment arms	
End point type	Primary
End point timeframe:	
8, 16, 32, 52 week intervals	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analysis

End point values	Sertraline hydrochloride (Arm A)	Arm B	Combination (Arm C)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	9	13	
Units: Y-BOCS				
number (not applicable)	15	18	16	

Attachments (see zip file)	Evaluation of YBOCS table.docx
----------------------------	--------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Montgomery Asberg Depression Rating Scale

End point title	Montgomery Asberg Depression Rating Scale
-----------------	---



End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Primary week 16 (please see attached table for other timepoints)

End point values	Sertraline hydrochloride (Arm A)	Arm B	Combination (Arm C)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	9	13	
Units: MADRS				
arithmetic mean (standard deviation)	8.1 (± 6.5)	14.9 (± 10.6)	12.6 (± 9.3)	

<b>Attachments (see zip file)</b>	Total MADRS scores table.docx
-----------------------------------	-------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Sheehan Disability Score

End point title	Sheehan Disability Score
-----------------	--------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Primary week 16 (for other time points see attached tables)

End point values	Sertraline hydrochloride (Arm A)	Arm B	Combination (Arm C)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	9	13	
Units: SD scores				
arithmetic mean (standard deviation)	13.5 (± 9.9)	13.8 (± 8.3)	9.3 (± 8.9)	

<b>Attachments (see zip file)</b>	Evaluation of CGI and SDS table.docx
-----------------------------------	--------------------------------------

### Statistical analyses

No statistical analyses for this end point

**Secondary: CGI Severity**

End point title	CGI Severity
-----------------	--------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Primary week 16 (for other time points see attached table)

End point values	Sertraline hydrochloride (Arm A)	Arm B	Combination (Arm C)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	9	13	
Units: CGI				
arithmetic mean (standard deviation)	3.7 (± 1.2)	4.3 (± 1.2)	4.1 (± 1.2)	

<b>Attachments (see zip file)</b>	Evaluation of CGI and SDS table.docx
-----------------------------------	--------------------------------------

**Statistical analyses**

No statistical analyses for this end point

**Secondary: CGI Improvement**

End point title	CGI Improvement
-----------------	-----------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Primary week 16 (for other time points see attached table)

End point values	Sertraline hydrochloride (Arm A)	Arm B	Combination (Arm C)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	9	13	
Units: CGI				
arithmetic mean (standard deviation)	3.2 (± 0.8)	3.6 (± 1.4)	3.4 (± 1.1)	

<b>Attachments (see zip file)</b>	Evaluation of CGI and SDS table.docx
-----------------------------------	--------------------------------------

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

52 weeks following randomisation

Adverse event reporting additional description:

The research psychiatrist assessed patients who are randomised to receive sertraline at weeks 2, 4, 8, 16, 24, 32 and 52.

The research nurse assessed all patients randomised to the CBT with ERP monotherapy arm at weeks 2, 4, 8, 16, 32 and 52 weeks

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0
--------------------	------

### Reporting groups

Reporting group title	Sertraline hydrochloride (Arm A)
-----------------------	----------------------------------

Reporting group description:

Sertraline hydrochloride Monotherapy

Reporting group title	Arm B
-----------------------	-------

Reporting group description:

Cognitive Behavioural Therapy (CBT) with Exposure Response Prevention monotherapy for a total of 16 hours over 8 weeks

Reporting group title	Combination (Arm C)
-----------------------	---------------------

Reporting group description:

A combination of Sertraline hydrochloride and Cognitive Behavioural Therapy (CBT) with Exposure Response Prevention (ERP)

Serious adverse events	Sertraline hydrochloride (Arm A)	Arm B	Combination (Arm C)
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 15 (13.33%)	1 / 18 (5.56%)	0 / 16 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Surgical and medical procedures			
Aborted pregnancy			
subjects affected / exposed	1 / 15 (6.67%)	1 / 18 (5.56%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	1 / 15 (6.67%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Sertraline hydrochloride (Arm A)	Arm B	Combination (Arm C)
Total subjects affected by non-serious adverse events subjects affected / exposed	10 / 15 (66.67%)	11 / 18 (61.11%)	16 / 16 (100.00%)
Investigations Weight gain subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 18 (5.56%) 1	4 / 16 (25.00%) 6
Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all)  Road traffic accident subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0  1 / 15 (6.67%) 1	1 / 18 (5.56%) 1  0 / 18 (0.00%) 0	0 / 16 (0.00%) 0  0 / 16 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 1
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)  Headache subjects affected / exposed occurrences (all)  Numbness in face subjects affected / exposed occurrences (all)  Slow speech	4 / 15 (26.67%) 6  4 / 15 (26.67%) 5  0 / 15 (0.00%) 0	0 / 18 (0.00%) 0  2 / 18 (11.11%) 2  1 / 18 (5.56%) 1	7 / 16 (43.75%) 7  8 / 16 (50.00%) 15  0 / 16 (0.00%) 0

subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Tremor			
subjects affected / exposed	2 / 15 (13.33%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences (all)	3	0	0
Vertigo			
subjects affected / exposed	1 / 15 (6.67%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 15 (6.67%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Decreased appetite			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	3
Feeling jittery			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Hot flush			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Irritability			
subjects affected / exposed	0 / 15 (0.00%)	1 / 18 (5.56%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Orofacial oedema			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Sweating			
subjects affected / exposed	3 / 15 (20.00%)	2 / 18 (11.11%)	9 / 16 (56.25%)
occurrences (all)	7	2	20
Tiredness			
subjects affected / exposed	5 / 15 (33.33%)	4 / 18 (22.22%)	7 / 16 (43.75%)
occurrences (all)	11	6	11
Ill-defined disorder			

subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	2 / 18 (11.11%) 2	0 / 16 (0.00%) 0
Social circumstances			
Refusal of treatment by patient subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 1
Sexual assault subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 1
Gastrointestinal disorders			
Abdominal Pain subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	1 / 18 (5.56%) 1	3 / 16 (18.75%) 3
Constipation subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 2
Diarrhoea subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	1 / 18 (5.56%) 1	2 / 16 (12.50%) 4
Dry mouth subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	1 / 18 (5.56%) 1	7 / 16 (43.75%) 15
Dyspepsia subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	0 / 18 (0.00%) 0	2 / 16 (12.50%) 5
Nausea subjects affected / exposed occurrences (all)	4 / 15 (26.67%) 6	4 / 18 (22.22%) 5	4 / 16 (25.00%) 14
Teeth grinding subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 6
Respiratory, thoracic and mediastinal disorders			
Yawning subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 2
Skin and subcutaneous tissue disorders			

Dermatitis contact subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Hair loss subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 18 (0.00%) 0	2 / 16 (12.50%) 2
Itching subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0
Psychiatric disorders			
Affect lability subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 1
Aggression subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Agitation subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	4 / 15 (26.67%) 8	5 / 18 (27.78%) 10	8 / 16 (50.00%) 22
Crying Abnormal subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 2
Daydreaming subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Delayed orgasm subjects affected / exposed occurrences (all)	6 / 15 (40.00%) 3	0 / 18 (0.00%) 0	2 / 16 (12.50%) 4
Depressed mood subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	3 / 18 (16.67%) 3	1 / 16 (6.25%) 1
Depression			



subjects affected / exposed	0 / 15 (0.00%)	1 / 18 (5.56%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Difficulty thinking			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Dissociation			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Emotional disorder			
subjects affected / exposed	0 / 15 (0.00%)	1 / 18 (5.56%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Insomnia			
subjects affected / exposed	7 / 15 (46.67%)	3 / 18 (16.67%)	8 / 16 (50.00%)
occurrences (all)	11	3	16
Apathy			
subjects affected / exposed	1 / 15 (6.67%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences (all)	3	0	0
Mental exhaustion			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Migraine			
subjects affected / exposed	0 / 15 (0.00%)	1 / 18 (5.56%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Nervousness			
subjects affected / exposed	2 / 15 (13.33%)	2 / 18 (11.11%)	6 / 16 (37.50%)
occurrences (all)	2	6	14
Panic attacks			
subjects affected / exposed	0 / 15 (0.00%)	3 / 18 (16.67%)	11 / 16 (68.75%)
occurrences (all)	0	3	1
Restlessness			
subjects affected / exposed	2 / 15 (13.33%)	1 / 18 (5.56%)	4 / 16 (25.00%)
occurrences (all)	3	1	7
Sexual desire decreased			
subjects affected / exposed	5 / 15 (33.33%)	1 / 18 (5.56%)	3 / 16 (18.75%)
occurrences (all)	5	1	6
Suicidal ideation			

subjects affected / exposed	0 / 15 (0.00%)	1 / 18 (5.56%)	2 / 16 (12.50%)
occurrences (all)	0	3	3
Time perception altered			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Vivid dreams			
subjects affected / exposed	2 / 15 (13.33%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	2	0	1
Musculoskeletal and connective tissue disorders			
Dislocated shoulder			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Fibula fracture			
subjects affected / exposed	1 / 15 (6.67%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Hand pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Jaw stiffness			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Muscle tension			
subjects affected / exposed	1 / 15 (6.67%)	1 / 18 (5.56%)	2 / 16 (12.50%)
occurrences (all)	3	1	3
Muscle twitching			
subjects affected / exposed	2 / 15 (13.33%)	1 / 18 (5.56%)	3 / 16 (18.75%)
occurrences (all)	3	1	5
Infections and infestations			
Influenza			
subjects affected / exposed	0 / 15 (0.00%)	0 / 18 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	2

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 January 2015	Change of address of CI. Pregnancy form introduced. RPs allowed to perform all screening. Patients permitted to collect study medication.
26 May 2015	Addition of further recruitment strategies. Allowing support of patients between visits. Decrease of wash out time. Clarifying follow up. Reference to use of social media removed
25 August 2015	Adverts for OCD Action website produced.
14 October 2015	Press release, advert for Trust TV screens and piece for R+D newsletter produced. Trained team members to administer CANTAB if necessary.
09 January 2017	Changes made to interview process to address feedback from REC.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/3011392>